FINWIRES · TerminalLIVE
FINWIRES

Oil, Middle East Views Dent Wall Street Pre-Bell; Asia, Europe Off

By

-- Wall Street futures pointed moderately lower pre-bell Thursday as global crude prices sustained gains, and as traders weighed reports of continued hostilities in the Persian Gulf.

After fresh all-time zeniths were struck on Wednesday, the S&P 500 fell 0.5%, and the Nasdaq also declined 0.5%, in the futures. The Dow Jones was off 0.7%.

With the Strait of Hormuz still blocked, West Texas Intermediate crude oil traded up 1.6% to $94.43 a barrel in morning action.

Asian exchanges traded mostly lower overnight, while European bourses tracked moderately lower midday on the continent.

United Rentals (URI) traded up 13.7% pre-bell after the equipment-rental outfit reported Q1 EPS and revenue above consensus, and issued upbeat guidance, late Wednesday.

Thermo Fisher Scientific (TMO) traded down 4.7% pre-bell after the lab-equipment maker reported fiscal Q1 EPS and revenue above expectations, but issued tempered guidance, in pre-bell hours.

On the economic calendar is the weekly jobless claims report at 8:30 am ET, along with the Chicago Fed National Activity Index for March.

The S&P Global flash US composite purchasing managers index (PMI) release logs at 9:45 am.

The weekly EIA natural gas report posts at 10:30 am, followed by the Kansas City Fed Manufacturing Index for April at 11 am.

In premarket action, Bitcoin traded at $77,307 and 10-year US Treasuries offered 4.32%. Spot gold commanded $4,688 an ounce.

Related Articles

Australia

Mizuho Securities Raises Price Target on Apellis Pharmaceuticals to $41 From $20, Maintains Neutral Rating

Apellis Pharmaceuticals (APLS) has an average rating of hold and mean price target of $40.82, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $40.95, Change: $-0.05, Percent Change: -0.11%

$APLS
Research

Mizuho Securities Downgrades Terns Pharmaceuticals to Neutral From Outperform, Trims Price Target to $53 From $54

Terns Pharmaceuticals (TERN) has an average rating of hold and mean price target of $53, according to analysts polled by FactSet.

$TERN
Research

Research Alert: CFRA Reiterates Buy Opinion On Shares Of Booking Holdings Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target price by $8 to $196, 19x our 2026 EPS estimate (unchanged) and a discount to its 23x five-year average forward multiple, reflecting geopolitical risks. We lower our 2026 EPS to $10.33 from $10.74 and 2027's to $11.58 from $12.07, primarily reflecting lower gross bookings growth from the Middle East conflict. We maintain our Buy opinion as shares are undervalued given long-term competitive strengths and temporary geopolitical headwinds. The company's Connected Trip platform and Genius loyalty program are supporting higher-margin direct bookings, suggesting AI initiatives are strengthening consumer engagement rather than disintermediating the platform. Strong free cash flow supports future shareholder returns, including $3.6 billion in Q1 buybacks. While the Middle East conflict will impact Q2 bookings, BKNG has a history of seeing travel rebound following geopolitical or economic disruptions. U.S. room night growth accelerated in Q1 to a low-teens range, providing near-term momentum.

$BKNG